|
[1]POLLHEIMER MJ, FICKERT P, STIEGER B.Chronic cholestatic liver diseases:Clues from histopathology for pathogenesis[J].Mol Aspects Med, 2014, 37:35-56.
|
|
[2]WELLS RG, SCHWABE RF.Origin and function of myofibroblasts in the liver[J].Semin Liver Dis, 2015, 35 (2) :e1.
|
|
[3]TSUCHIDA T, FRIEDMAN SL.Mechanisms of hepatic stellate cell activation[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (7) :397-411.
|
|
[4]FRIEDMAN SL.Hepatic stellate cells:Protean, multifunctional, and enigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172.
|
|
[5]HIGASHI T, FRIEDMAN SL, HOSHIDA Y.Hepatic stellate cells as key target in liver fibrosis[J].Adv Drug Deliv Rev, 2017, 121:27-42.
|
|
[6]MEDERACKE I, HSU CC, TROEGER JS, et al.Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology[J].Nat Commun, 2013, 4:2823.
|
|
[7]IWAISAKO K, JIANG C, ZHANG M, et al.Origin of myofibroblasts in the fibrotic liver in mice[J].Proc Natl Acad Sci U S A, 2014, 111 (32) :e3297-e3305.
|
|
[8]DRANOFF JA, WELLS RG.Portal fibroblasts:Underappreciated mediators of biliary fibrosis[J].Hepatology, 2010, 51 (4) :1438-1444.
|
|
[9]KINNMAN N, HOUSSET C.Peribiliary myofibroblasts in biliary type liver fibrosis[J].Front Biosci, 2002, 7:d496-d503.
|
|
[10]KISSELEVA T, UCHINAMI H, FEIRT N, et al.Bone marrowderived fibrocytes participate in pathogenesis of liver fibrosis[J].J Hepatol, 2006, 45 (3) :429-438.
|
|
[11]SCHOLTEN D, OSTERREICHER CH, SCHOLTEN A, et al.Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice[J].Gastroenterology, 2010, 139 (3) :987-998.
|
|
[12]CHU AS, DIAZ R, HUI JJ, et al.Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis[J].Hepatology, 2011, 53 (5) :1685-1695.
|
|
[13]JANSEN PL, GHALLAB A, VARTAK N, et al.The ascending pathophysiology of cholestatic liver disease[J].Hepatology, 2017, 65 (2) :722-738.
|
|
[14]YIN XM, DING WX.Death receptor activation-induced hepatocyte apoptosis and liver injury[J].Curr Mol Med, 2003, 3 (6) :491-508.
|
|
[15]BORGOGNONE M, PREZ LM, BASIGLIO CL, et al.Signaling modulation of bile salt-induced necrosis in isolated rat hepatocytes[J].Toxicol Sci, 2005, 83 (1) :114-125.
|
|
[16]SAKISAKA S, KAWAGUCHI T, TANIGUCHI E, et al.Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis[J].Hepatology, 2001, 33 (6) :1460-1468.
|
|
[17]HOHENESTER S, WENNIGER LM, PAULUSMA CC, et al.Abiliary HCO-3umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes[J].Hepatology, 2012, 55 (1) :173-183.
|
|
[18]MEDINA JF, MARTNEZ-ANS, VAZQUEZ JJ, et al.Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis[J].Hepatology, 1997, 25 (1) :12-17.
|
|
[19]WILLIAMS MJ, CLOUSTON AD, FORBES SJ.Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion[J].Gastroenterology, 2014, 146 (2) :349-356.
|
|
[20]ROSKAMS TA, THEISE ND, BALABAUD C, et al.Nomenclature of the finer branches of the biliary tree:Canals, ductules, and ductular reactions in human livers[J].Hepatology, 2004, 39 (6) :1739-1745.
|
|
[21]ROSKAMS T, DESMET V.Ductular reaction and its diagnostic significance[J].Semin Diagn Pathol, 1998, 15 (4) :259-269.
|
|
[22]STRAZZABOSCO M, FABRIS L.Development of the bile ducts:Essentials for the clinical hepatologist[J].J Hepatol, 2012, 56 (5) :1159-1170.
|
|
[23]KINNMAN N, FRANCOZ C, BARBU V, et al.The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis[J].Lab Invest, 2003, 83 (2) :163-173.
|
|
[24]PRIESTER S, WISE C, GLASER SS.Involvement of cholangiocyte proliferation in biliary fibrosis[J].World J Gastrointest Pathophysiol, 2010, 1 (2) :30-37.
|
|
[25]VARTAK N, DAMLE-VARTAK A, RICHTER B, et al.Cholestasis-induced adaptive remodeling of interlobular bile ducts[J].Hepatology, 2016, 63 (3) :951-964.
|
|
[26]POUPON RE, BONNAND AM, CHRTIEN Y, et al.Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.The UDCA-PBC Study Group[J].Hepatology, 1999, 29 (6) :1668-1671.
|
|
[27] TRAUNER M, FUCHS CD, HALILBASIC E, et al.New therapeutic concepts in bile acid transport and signaling for management of cholestasis[J].Hepatology, 2017, 65 (4) :1393-1404.
|
|
[28]GERKEN G, NITSCHMANN S.Obeticholic acid in primary biliary cholangitis:PBC OCA international study of efficacy (POISE) [J].Internist (Berl) , 2017, 58 (2) :202-204.
|
|
[29]LEUSCHNER M, MAIER KP, SCHLICHTING J, et al.Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis:Results of a prospective double-blind trial[J].Gastroenterology, 1999, 117 (4) :918-925.
|
|
[30]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323.
|
|
[31]RAUTIAINEN H, KRKKINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:A three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.
|
|
[32]PATSENKER E, POPOV Y, STICKEL F, et al.Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression[J].Gastroenterology, 2008, 135 (2) :660-670.
|
|
[33]PENG ZW, IKENAGA N, LIU SB, et al.Integrinανβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis[J].Hepatology, 2016, 63 (1) :217-232.
|
|
[34]HAZRA S, XIONG S, WANG J, et al.Peroxisome proliferatoractivated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells[J].J Biol Chem, 2004, 279 (12) :11392-11401.
|
|
[35]STAELS B, RUBENSTRUNK A, NOEL B, et al.Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].Hepatology, 2013, 58 (6) :1941-1952.
|
|
[36]RATZIU V, HARRISON SA, FRANCQUE S, et al.Elafibranor, an agonist of the peroxisome proliferator-activated receptor-αand-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J].Gastroenterology, 2016, 150 (5) :1147-1159.
|
|
[37]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :Amulticentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965.
|
|
[38]MEISSNER EG, McLAUGHLIN M, MATTHEWS L, et al.Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults:Results of a 6-month open-label safety trial[J].Liver Int, 2016, 36 (12) :1783-1792.
|
DownLoad: